Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Neurology, Medicine, Duke University 1993 - 1994
  • Resident in Neurology, Medicine, Duke University 1990 - 1993
  • Medical Intern, Medicine, Northwestern University 1989 - 1990
  • M.D., University of Illinois 1989
• 

  Previous Appointments & Affiliations

  • Associate Professor of Neurology, Neurology, Neuromuscular Disease, Neurology 2005 - 2017
  • Instructor, Temporary in the Department of Medicine, Neurology, Clinical Science Departments 2004 - 2005
• 

  Academic Positions Outside Duke

  • Associate Professor of Neurology with Tenure, University of Virginia School of Medicine. 2004
  • Associate Professor of Neurology, University of Virginia School of Medicine. 2000 - 2004
  • Assistant Professor of Neurology, University of Virginia School of Medicine. 1994 - 2000
• Research
• 

  Selected Grants

  • Alexion ALXN1720-MG-301 awarded by Alexion Pharmaceuticals, Inc. 2023 - 2028
  • Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies awarded by Alexion Pharmaceuticals, Inc. 2020 - 2025
  • A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients with Generalized Myasthenia Gravis awarded by Alexion Pharmaceuticals, Inc. 2019 - 2023
  • RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS awarded by The George Washington University 2021 - 2023
  • RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (ADAPT) awarded by The George Washington University 2020 - 2023
  • RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Career Enhancement) awarded by The George Washington University 2019 - 2023
  • RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS (Site Agreement) awarded by The George Washington University 2019 - 2023
  • PROMISE-MG: PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY OF COMPARATIVE EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MYASTHENIA GRAVIS awarded by Patient Centered Outcomes Research Institute 2017 - 2021
  • VTEU Task C Option 1 Protocol 14-0024.C1D1.0037 awarded by National Institutes of Health 2018 - 2020
  • VTEU Task C Base Protocol 14-0024.C1D1.0037 awarded by National Institutes of Health 2015 - 2020
  • VTEU Task D Option 2 Protocol 14-0024.C1D1.0037 awarded by National Institutes of Health 2015 - 2020
  • VTEU Task D Option 4 Protocol 14-0024.C1D1.0037 awarded by National Institutes of Health 2015 - 2020
  • VTEU Task D Option 5 Protocol 14-0024.C1D1.0037 awarded by National Institutes of Health 2015 - 2020
  • A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis awarded by Alexion Pharmaceuticals, Inc. 2014 - 2019
  • VTEU Task D Option 3 Protocol 14-0024.C1D1.0037 awarded by National Institutes of Health 2015 - 2019
  • AANEM Autoimmune Neuromuscular Disorders Fellowship awarded by AANEM Foundation for Research & Education 2017 - 2018
  • A Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Generalized Refractory Myasthenia Gravis (GMG) awarded by Alexion Pharmaceuticals, Inc. 2014 - 2017
• 

  External Relationships

  • Accordant Health Services
  • Alexion Pharmaceuticals, Inc.
  • Immunovant
  • argenx US, Inc
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Masi G, Pham MC, Karatz T, Oh S, Payne AS, Nowak RJ, et al. Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. Ann Clin Transl Neurol. 2023 May;10(5):825–31.
       Full Text  Link to Item
    • Harada Y, Wang S-H, Juel VC. Clinical Reasoning: A 36-Year-Old Man With Asymmetric Muscle Weakness. Neurology. 2022 Sep 21;
       Full Text  Link to Item
    • Raja SM, Guptill JT, Juel VC, Walter EB, Cohen-Wolkowiez M, Hill H, et al. First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0173221.
       Full Text  Link to Item
    • Gonzalez NL, Juel VC, Živković SA. A Case of Probable Multifocal Motor Neuropathy With Clinical Stability for Ten Years After a Single Treatment of Rituximab. J Clin Neuromuscul Dis. 2022 Mar 1;23(3):136–42.
       Full Text  Link to Item
    • Siddiqi ZA, Nowak RJ, Mozaffar T, O’Brien F, Yountz M, Patti F, et al. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021 Dec;64(6):662–9.
       Full Text  Link to Item
    • Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 Jul;9(7).
       Full Text  Link to Item
    • Guptill JT, Raja SM, Juel VC, Walter EB, Cohen-Wolkowiez M, Hill H, et al. Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0232920.
       Full Text  Link to Item
    • Guptill JT, Barfield R, Chan C, Russo MA, Emmett D, Raja S, et al. Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle Nerve. 2021 Apr;63(4):577–85.
       Full Text  Link to Item
    • Li Y, Emmett CD, Cobbaert M, Sanders DB, Juel VC, Hobson-Webb LD, et al. Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis. Muscle Nerve. 2021 Mar;63(3):357–64.
       Full Text  Link to Item
    • Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853–65.
       Full Text  Link to Item
    • Sanders DB, Raja SM, Guptill JT, Hobson-Webb LD, Juel VC, Massey JM. The Duke myasthenia gravis clinic registry: I. Description and demographics. Muscle Nerve. 2021 Feb;63(2):209–16.
       Full Text  Link to Item
    • Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. Jama Neurol. 2021 Feb 1;78(2):186–96.
       Full Text  Link to Item
    • Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O’Brien FL, et al. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology. 2021 Jan 26;96(4):e610–8.
       Full Text  Link to Item
    • Li Y, Guptill JT, Russo MA, Howard JF, Massey JM, Juel VC, et al. Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. J Neuroimmunol. 2020 Aug 15;345:577279.
       Full Text  Link to Item
    • Mantegazza R, O’Brien FL, Yountz M, Howard JF, REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020 Aug;7(8):1327–39.
       Full Text  Link to Item
    • Vissing J, Jacob S, Fujita KP, O’Brien F, Howard JF, REGAIN study group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Jul;267(7):1991–2001.
       Full Text  Link to Item
    • Yi JS, Russo MA, Raja S, Massey JM, Juel VC, Shin J, et al. Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis. Exp Neurol. 2020 Mar;325:113146.
       Full Text  Link to Item
    • Raja SM, Howard JF, Juel VC, Massey JM, Chopra M, Guptill JT. Clinical outcome measures following plasma exchange for MG exacerbation. Ann Clin Transl Neurol. 2019 Oct;6(10):2114–9.
       Full Text  Link to Item
    • Raja SM, Sanders DB, Juel VC, Harati Y, Smith AG, Pascuzzi R, et al. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. Muscle Nerve. 2019 Sep;60(3):292–8.
       Full Text  Link to Item
    • Andersen H, Mantegazza R, Wang JJ, O’Brien F, Patra K, Howard JF, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2247–54.
       Full Text  Link to Item
    • Andersen H, Mantegazza R, Wang JJ, O’Brien F, Patra K, Howard JF, et al. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019 Aug;28(8):2255.
       Full Text  Link to Item
    • Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14–24.
       Full Text  Link to Item
    • Guidon AC, Juel VC. Efgartigimod: A novel antibody depletion therapy in myasthenia gravis. Neurology. 2019 Jun 4;92(23):1079–80.
       Full Text  Link to Item
    • Juel VC. Repetitive nerve stimulation testing in myasthenic crisis. Muscle Nerve. 2019 May;59(5):528–30.
       Full Text  Link to Item
    • Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019 Mar;18(3):259–68.
       Full Text  Link to Item
    • Li Y, Guptill JT, Russo MA, Massey JM, Juel VC, Hobson-Webb LD, et al. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Exp Neurol. 2019 Feb;312:43–50.
       Full Text  Link to Item
    • Juel VC. Single fiber electromyography. Handb Clin Neurol. 2019;160:303–10.
       Full Text  Link to Item
    • Juel VC. Clinical neurophysiology of neuromuscular junction disease. Handb Clin Neurol. 2019;161:291–303.
       Full Text  Link to Item
    • Sabre L, Guptill JT, Russo M, Juel VC, Massey JM, Howard JF, et al. Circulating microRNA plasma profile in MuSK+ myasthenia gravis. J Neuroimmunol. 2018 Dec 15;325:87–91.
       Full Text  Link to Item
    • Sanders DB, Harati Y, Juel VC, Lou J-S, Marburger T, Pascuzzi RM, et al. Reply. Muscle Nerve. 2018 May;57(5):E130–1.
       Full Text  Link to Item
    • Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, et al. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018 Apr;57(4):561–8.
       Full Text  Link to Item
    • Sanders DB, Guptill JT, Aleš KL, Hobson-Webb LD, Jacobus DP, Mahmood R, et al. Reliability of the triple-timed up-and-go test. Muscle Nerve. 2018 Jan;57(1):136–9.
       Full Text  Link to Item
    • Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 Dec;16(12):976–86.
       Full Text  Link to Item
    • Juel VC, Sanders DB, Hobson-Webb LD, Massey JM, Guptill JT, O’Brien F, et al. Marked clinical and jitter improvement after eculizumab in refractory myasthenia. Muscle Nerve. 2017 Sep;56(3):E16–8.
       Full Text  Link to Item
    • Hobson-Webb LD, Juel VC. Common Entrapment Neuropathies. Continuum (Minneap Minn). 2017 Apr;23(2, Selected Topics in Outpatient Neurology):487–511.
       Full Text  Link to Item
    • Yi JS, Russo MA, Massey JM, Juel V, Hobson-Webb LD, Gable K, et al. B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity. Front Neurol. 2017;8:34.
       Full Text  Open Access Copy  Link to Item
    • Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016 Dec;54(6):1015–22.
       Full Text  Link to Item
    • Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016 Nov;49(7):472–9.
       Full Text  Link to Item
    • Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Muscle Nerve. 2016 Mar;53(3):363–9.
       Full Text  Link to Item
    • Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, et al. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb;53(2):165–8.
       Full Text  Link to Item
    • Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, et al. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2015 Apr;2(2):e77.
       Full Text  Open Access Copy  Link to Item
    • Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI, Tirasemtiv in Myasthenia Gravis Study Group. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics. 2015 Apr;12(2):455–60.
       Full Text  Link to Item
    • Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014 Oct;50(4):477–87.
       Full Text  Link to Item
    • Yi JS, Guidon A, Sparks S, Osborne R, Juel VC, Massey JM, et al. Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun. 2014 Aug;52:130–8.
       Full Text  Open Access Copy  Link to Item
    • Sanders DB, Cao L, Massey JM, Juel VC, Hobson-Webb L, Guptill JT. Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis? Clin Neurophysiol. 2014 Jun;125(6):1274–7.
       Full Text  Link to Item
    • Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014 Apr;49(4):483–6.
       Full Text  Link to Item
    • Choi Decroos E, Hobson-Webb LD, Juel VC, Massey JM, Sanders DB. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve. 2014 Jan;49(1):30–4.
       Full Text  Link to Item
    • Howard JF, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 Jul;48(1):76–84.
       Full Text  Link to Item
    • Hobson-Webb LD, Juel VC. The three dimensional assessment of peripheral nerve injury: an integrated clinical, neurophysiologic and sonographic approach. Clin Neurophysiol. 2013 Jun;124(6):1053–4.
       Full Text  Link to Item
    • Hobson-Webb LD, Massey JM, Juel VC. Nerve ultrasound in diabetic polyneuropathy: correlation with clinical characteristics and electrodiagnostic testing. Muscle Nerve. 2013 Mar;47(3):379–84.
       Full Text  Link to Item
    • Guptill JT, Oakley D, Kuchibhatla M, Guidon AC, Hobson-Webb LD, Massey JM, et al. A retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve. 2013 Feb;47(2):170–6.
       Full Text  Link to Item
    • Mhoon JT, Juel VC, Hobson-Webb LD. Median nerve ultrasound as a screening tool in carpal tunnel syndrome: correlation of cross-sectional area measures with electrodiagnostic abnormality. Muscle Nerve. 2012 Dec;46(6):871–8.
       Full Text  Link to Item
    • Juel VC. Evaluation of neuromuscular junction disorders in the electromyography laboratory. Neurol Clin. 2012 May;30(2):621–39.
       Full Text  Link to Item
    • Hobson-Webb LD, Mhoon JT, Juel VC. Effect of transducer frequency on muscle luminosity ratio. Muscle Nerve. 2011 Oct;44(4):612–3.
       Full Text  Link to Item
    • Selcen D, Juel VC, Hobson-Webb LD, Smith EC, Stickler DE, Bite AV, et al. Myasthenic syndrome caused by plectinopathy. Neurology. 2011 Jan 25;76(4):327–36.
       Full Text  Link to Item
    • Mhoon JT, Nandigam K, Juel VC. Teaching video NeuroImages: painful legs and moving toes syndrome. Neurology. 2010 Jul 13;75(2):e6.
       Full Text  Link to Item
    • Ephgrave K, Margo KL, White C, Hammoud M, Brodkey A, Painter T, et al. Core clerkship directors: their current resources and the rewards of the role. Acad Med. 2010 Apr;85(4):710–5.
       Full Text  Link to Item
    • Burns TM, Grouse CK, Conaway MR, Sanders DB, mg composite and mg-qol15 study group. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010 Feb;41(2):219–26.
       Full Text  Link to Item
    • Juel VC. Myasthenic crisis: smoother sailing ahead. Eur J Neurol. 2009 Jul;16(7):775–6.
       Full Text  Link to Item
    • Hobson-Webb L, Massey JM, Juel VC, Sanders DB. Reply to "Diagnostic value of wrist median nerve cross sectional area versus wrist-to-forearm ratio in carpal tunnel syndrome". Clinical Neurophysiology. 2008 Dec 1;119(12):2899.
       Full Text
    • Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol. 2008 Sep 15;201–202:85–9.
       Full Text  Link to Item
    • Hobson-Webb LD, Massey JM, Juel VC, Sanders DB. The ultrasonographic wrist-to-forearm median nerve area ratio in carpal tunnel syndrome. Clin Neurophysiol. 2008 Jun;119(6):1353–7.
       Full Text  Link to Item
    • Mahadeva B, Phillips LH, Juel VC. Autoimmune disorders of neuromuscular transmission. Semin Neurol. 2008 Apr;28(2):212–27.
       Full Text  Link to Item
    • Sanders DB, Juel VC. The Lambert-Eaton myasthenic syndrome. Handb Clin Neurol. 2008;91:273–83.
       Full Text  Link to Item
    • Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007 Nov 6;2:44.
       Full Text  Open Access Copy  Link to Item
    • Scherer K, Skeen MB, Strine SA, Juel VC. Hanging leg syndrome: combined bilateral femoral and sciatic neuropathies. Neurology. 2006 Apr 11;66(7):1124–5.
       Full Text  Link to Item
    • American Association of Neuromuscular & Electrodiagnostic Medicine. Needle EMG in certain uncommon clinical contexts. Muscle Nerve. 2005 Mar;31(3):398–9.
       Full Text  Link to Item
    • Juel VC, Massey JM. Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation. Curr Treat Options Neurol. 2005 Jan;7(1):3–14.
       Full Text  Link to Item
    • Morgan JC, Cavaliere R, Juel VC. Reversible corpus callosum lesion in legionnaires' disease. J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):651–4.
       Full Text  Link to Item
    • Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004 Mar;24(1):75–81.
       Full Text  Link to Item
    • Swerdlow RH, Juel VC, Wooten GF. Dystonia with and without deafness is caused by TIMM8A mutation. Adv Neurol. 2004;94:147–54.
       Link to Item
    • Winter WC, Juel VC. Hypoglossal neuropathy in hereditary neuropathy with liability to pressure palsy. Neurology. 2003 Oct 28;61(8):1154–5.
       Full Text  Link to Item
    • Juel VC, Johnston KC. Predict Resident Exam Performance (PREP) study. Neurology. 2003 Apr 22;60(8):1385–7.
       Full Text  Link to Item
    • Minassian BA, Aiyar R, Alic S, Banwell B, Villanova M, Fardeau M, et al. Narrowing in on the causative defect of an intriguing X-linked myopathy with excessive autophagy. Neurology. 2002 Aug 27;59(4):596–601.
       Full Text  Link to Item
    • Jääskeläinen SK, Juel VC, Udd B, Villanova M, Liguori R, Minassian BA, et al. Electrophysiological findings in X-linked myopathy with excessive autophagy. Ann Neurol. 2002 May;51(5):648–52.
       Full Text  Link to Item
    • Wing Y-K, Li RH-Y, Lam C-W, Ho CK-W, Fong SY-Y, Leung T. The prevalence of narcolepsy among Chinese in Hong Kong. Ann Neurol. 2002 May;51(5):578–84.
       Full Text  Link to Item
    • Burns TM, Shneker BF, Juel VC. Gasoline sniffing multifocal neuropathy. Pediatr Neurol. 2001 Nov;25(5):419–21.
       Full Text  Link to Item
    • Burns MT, Juel VC, Hess CE, Phillips LH. Motor neuron disease and serum monoclonal proteins: poor response to treatment of the paraproteinemia. J Clin Neuromuscul Dis. 2000 Dec;2(2):70–2.
       Full Text  Link to Item
    • Juel VC, Kiely JM, Leone KV, Morgan RF, Smith T, Phillips LH. Isolated musculocutaneous neuropathy caused by a proximal humeral exostosis. Neurology. 2000 Jan 25;54(2):494–6.
       Full Text  Link to Item
    • Simmad VI, Juel VC, Phillips LH. Clinical and electrophysiological findings in the migrant sensory 'neuritis' of wartenberg. J Clin Neuromuscul Dis. 1999 Sep;1(1):6–10.
       Full Text  Link to Item
    • Phillips LH, Juel VC. Myasthenia gravis in the tenth decade. Muscle Nerve. 1999 Sep;22(9):1297–8.
       Full Text  Link to Item
    • Burns TM, Juel VC, Sanders DB, Phillips LH. Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology. 1999 Apr 22;52(7):1490–1.
       Full Text  Link to Item
    • Swerdlow RH, Parks JK, Cassarino DS, Trimmer PA, Miller SW, Maguire DJ, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol. 1998 Sep;153(1):135–42.
       Full Text  Link to Item
    • Vern BA, Leheta BJ, Juel VC, LaGuardia J, Graupe P, Schuette WH. Slow oscillations of cytochrome oxidase redox state and blood volume in unanesthetized cat and rabbit cortex. Interhemispheric synchrony. Adv Exp Med Biol. 1998;454:561–70.
       Full Text  Link to Item
    • Vern BA, Leheta BJ, Juel VC, LaGuardia J, Graupe P, Schuette WH. Interhemispheric synchrony of slow oscillations of cortical blood volume and cytochrome aa3 redox state in unanesthetized rabbits. Brain Res. 1997 Nov 14;775(1–2):233–9.
       Full Text  Link to Item
    • Phillips LH, Juel VC. The role of electrodiagnostic testing in carpal tunnel syndrome. Neurosurg Focus. 1997 Jul 15;3(1):e2.
       Full Text  Link to Item
    • Ballard R, Tien RD, Nohria V, Juel V. The Chédiak-Higashi syndrome: CT and MR findings. Pediatr Radiol. 1994;24(4):266–7.
       Full Text  Link to Item
    • Vern BA, Schuette WH, Leheta B, Juel VC, Radulovacki M. Low-frequency oscillations of cortical oxidative metabolism in waking and sleep. J Cereb Blood Flow Metab. 1988 Apr;8(2):215–26.
       Full Text  Link to Item
    • Vern BA, Schuette WH, Juel VC, Radulovacki M. A simplified method for monitoring the cytochrome aa3 redox state in bilateral cortical areas of unanesthetized cats. Brain Res. 1987 Jul 7;415(1):188–93.
       Full Text  Link to Item

  • Book Sections

    • Tarawneh R, Juel VC. The Neuromuscular Junction and Myasthenia Gravis. In: Novel Challenges in Myasthenia Gravis. 2015. p. 51–66.

  • Conference Papers

    • Harada Y, Bettin M, Juel VC, Hobson-Webb LD, Raja SM, Sanders DB, et al. Pregnancy in MuSK-positive myasthenia gravis: A single-center case series. In: Muscle Nerve. 2023.
       Full Text  Link to Item
    • Sanders DB, Lutz MW, Raja SM, Juel VC, Guptill JT, Hobson-Webb LD, et al. The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes. In: Muscle Nerve. 2023. p. 291–6.
       Full Text  Link to Item
    • Juel V, Vu T, Casasnovas C, Uzawa A, Aguzzi R, Frick G, et al. CONSISTENT EFFICACY OF RAVULIZUMAB ACROSS SEX AND AGE SUBGROUPS OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: A POST HOC ANALYSIS OF THE CHAMPION MG STUDY. In: Muscle & Nerve. 2022. p. S1–2.
       Link to Item
    • Raja SM, Sanders DB, Juel VC, Guptill JT, Hobson-Webb LD, Massey JM. THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: THYMECTOMY IN MUSK MYASTHENIA. In: Muscle & Nerve. 2022. p. S39–S39.
       Link to Item
    • Sanders DB, Raja SM, Juel VC, Guptill JT, Hobson-Webb LD, Massey JM. THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: SINGLE FIBER EMG FINDINGS. In: Muscle & Nerve. 2022. p. S23–S23.
       Link to Item
    • Mantri S, Berry C, Juel V. Neuro-Jeopardy and Neurophobia: Lessons from a Pilot Intervention. In: Neurology. 2021.
       Link to Item
    • Raja S, Sanders D, Bettin M, Curtis J, Guptill J, Hobson-Webb L, et al. ANALYSIS OF THE DUKE MYASTHENIA GRAVIS (MG) CLINIC REGISTRY: THYMECTOMY. In: Muscle & Nerve. 2021. p. S83–S83.
       Link to Item
    • Sanders D, Cutter G, Juel V, Guptill J, Hobson-Webb L, Raja S, et al. THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: FACTORS PREDICTING GENERALIZATION OF OCULAR MG. In: Muscle & Nerve. 2021. p. S81–S81.
       Link to Item
    • Sanders D, Juel V, Guptill J, Hobson-Webb L, Raja S, Massey J. THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: SINGLE FIBER EMG FINDINGS. In: Muscle & Nerve. 2021. p. S80–S80.
       Link to Item
    • Guptill J, Howard J, Russo M, Emmett D, Chopra M, Juel V, et al. Effect of Complement Inhibition on Lymphocytes in Treatment Refractory Myasthenia Gravis Patients. In: Neurology. 2020.
       Link to Item
    • Li X, Gable K, Juel V. IMMUNE CHECKPOINT INHIBITOR MEDIATED INFLAMMATORY POLYNEUROPATHY. In: Muscle & Nerve. 2020. p. S19–S19.
       Link to Item
    • Li Y, Emmett C, Cobbaert M, Sanders D, Juel V, Hobson-Webb L, et al. KNOWLEDGE AND PERCEPTIONS OF THE COVID-19 PANDEMIC AMONG PATIENTS WITH MYASTHENIA GRAVIS. In: Muscle & Nerve. 2020. p. S121–S121.
       Link to Item
    • Sanders D, Raja S, Guptill J, Hobson-Webb L, Juel V, Massey J. Analysis of the Duke Myasthenia Gravis (MG) Clinic Registry: Demographic and Clinical Characteristics. In: Neurology. 2020.
       Link to Item
    • Sanders D, Raja S, Juel V, Guptill J, Hobson-Webb L, Massey J. THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS. In: Muscle & Nerve. 2020. p. S96–S96.
       Link to Item
    • Sanders D, Raja S, Juel V, Guptill J, Hobson-Webb L, Massey J. THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS. In: Muscle & Nerve. 2020. p. S114–S114.
       Link to Item
    • Gable K, Juel V. OCULAR NON-THYMOMATOUS SEROPOSITIVE MYASTHENIA GRAVIS WITH MINIMAL DISEASE MANIFESTATIONS ASSOCIATED WITH ACQUIRED RIPPLING MUSCLE DISEASE. In: Muscle & Nerve. 2019. p. S122–S122.
       Link to Item
    • Gonzalez N, Guptill J, Hobson-Webb L, Juel V, Gable K. NERVE ROOT HYPERTROPHY CAUSING SPINAL STENOSIS IN HEREDITARY AND AUTOIMMUNE DEMYELINATING NEUROPATHY. In: Muscle & Nerve. 2019. p. S107–S107.
       Link to Item
    • Li Y, Russo M, Massey J, Juel V, Hobson-Webb L, Howard J, et al. Tacrolimus Inhibits Th1 and Th17 Responses in MuSK-MG Patients. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2018.
       Link to Item
    • Raja S, Juel V, Massey J, Hobson-Webb L, Guptill J, Gable K, et al. Lambert-Eaton Myasthenia With and Without Cancer: Clinical Characteristics and Long-term Survival. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2018.
       Link to Item
    • Gonzalez N, Juel V, Zivkovic S. A case of remission from multifocal motor neuropathy following rituximab. In: Neurology. 2018.
       Link to Item
    • Li Y, Guptill J, Russo M, Massey J, Juel V, Hobson-Webb L, et al. MUSK MYASTHENIA GRAVIS IS ASSOCIATED WITH AN IMBALANCE IN TFH17 CELL SUBSETS. In: Muscle & Nerve. 2018. p. S117–S117.
       Link to Item
    • Raja S, Sanders D, Juel V, Harati Y, Smith A, Peltier A, et al. VALIDATION OF THE TRIPLE TIMED UP-AND-GO TEST FOR CLINICAL ASSESSMENT IN LAMBERT-EATON MYASTHENIA PATIENTS. In: Muscle & Nerve. 2018. p. S106–S106.
       Link to Item
    • Raja S, Sanders D, Juel V, Harati Y, Smith AG, Peltier A, et al. VALIDATION OF THE TRIPLE TIMED UP-AND-GO TEST FOR CLINICAL ASSESSMENT IN LAMBERT-EATON MYASTHENIA PATIENTS. In: Muscle & Nerve. 2018. p. S4–S4.
       Link to Item
    • Thakkar N, Guptill JT, Aleš K, Jacobus D, Jacobus L, Peloquin C, et al. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia. In: Cpt Pharmacometrics Syst Pharmacol. 2017. p. 625–34.
       Full Text  Link to Item
    • Das S, Gable K, Juel V. Impact of Review Sessions on NBME Subject Examination Performance. In: Neurology. 2017.
       Link to Item
    • Guptill J, Juel V, Massey J, Chopra M, Howard J. Effects of Therapeutic Plasma Exchange on Myasthenic Outcome Measures. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2016.
       Link to Item
    • Yi J, Russo M, Massey J, Juel V, Hobson-Webb L, Gable K, et al. B10 DEFICIENCY IN MYASTHENIA GRAVIS IS NOT ASSOCIATED WITH DEFECTIVE T CELL SUPPRESSION. In: Muscle & Nerve. 2016. p. 641–641.
       Link to Item
    • Guptill JT, Juel VC, Massey JM, Anderson AC, Yi JS, Chopra M, et al. EFFECT OF THERAPEUTIC PLASMA EXCHANGE ON IMMUNOGLOBULINS. In: Muscle & Nerve. WILEY-BLACKWELL; 2015. p. S140–S140.
       Link to Item
    • Sanders DB, Juel VC, Harati Y, Smith AG, Peltier A, Marburger T, et al. RESULTS FROM THE DAPPER STUDY: INPATIENT DOUBLE-BLIND PLACEBO-CONTROLLED WITHDRAWAL STUDY OF 3,4-DIAMINOPYRIDINE BASE (3,4-DAP) IN SUBJECTS WITH LAMBERTEATON MYASTHENIC SYNDROME (LEMS). In: Muscle & Nerve. WILEY-BLACKWELL; 2015. p. S141–S141.
       Link to Item
    • Sanders DB, Juel VC, Harati Y, Smith AG, Peltier A, Marburger T, et al. Results of a Double-Blind Placebo-Controlled Study of 3,4-Diaminopyridine (DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS). In: Annals of Neurology. WILEY-BLACKWELL; 2015. p. S104–S104.
       Link to Item
    • Hobson-Webb LD, Guptill JT, Russo MA, Anderson AC, Massey JM, Gable K, et al. T CELL REACTIVITY IN INCLUSION BODY MYOSITIS (IBM). In: Muscle & Nerve. WILEY-BLACKWELL; 2015. p. S11–S11.
       Open Access Copy  Link to Item
    • Sanders D, Juel V, Harati Y, Smith AG, Peltier A, Marburger T, et al. RESULTS FROM THE DAPPER STUDY: INPATIENT DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY OF 3,4-DIAMINOPYRIDINE BASE (3,4-DAP) IN SUBJECTS WITH LAMBERT-EATON MYASTHENIC SYNDROME. In: Muscle & Nerve. 2015. p. S13–S13.
       Link to Item
    • Juel VC, Sanders DB, Hobson-Webb LD, Massey JM, Guptill JT, O’Brien F, et al. PARALLEL CLINICAL AND JITTER CHANGES DURING RAPID, ECULIZUMAB-INDUCED MYASTHENIC REMISSION. In: Muscle & Nerve. WILEY-BLACKWELL; 2014. p. 718–718.
       Link to Item
    • Yi JS, Sanders DB, Massey JM, Juel VC, Weinhold KJ, Guptill JT. COMPARISON OF B10 CELLS IN IMMUNOSLTPPRESSED AND IMMUNOSUPPRESSION NAIVE ACHR plus MG. In: Muscle & Nerve. WILEY-BLACKWELL; 2014. p. 716–716.
       Link to Item
    • Sanders D, Burns T, Cutter G, Massey J, Juel V, Hobson-Webb L. Does Change in Acetylcholine Receptor Antibody (AChR-Ab) Level Predict or Correlate with Clinical Change in Myasthenia Gravis (MG)? In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2013.
       Link to Item
    • De Jesus-Acosta C, Hobson-Webb L, Juel V. Muscle Ultrasonography Changes over One Year in Duchenne and Becker Muscular Dystrophy. In: Neurology. 2013.
       Link to Item
    • Kushlaf H, Juel V, Hobson-Webb L. Upper Extremity Peripheral Nerve Ultrasound Shows Proximal to Distal Tapering of Nerves in Demyelinating Charcot-Marie-Tooth Disease but Not in Acquired Inflammatory Demyelinating Neuropathies. In: Neurology. 2013.
       Link to Item
    • Kushlaf HA, Juel VC, Hobson-Webb LD. DO ULTRASOUND CHARACTERISTICS CORRELATE WITH ELECTRODIAGNOSTIC FINDINGS IN INFLAMMATORY NEUROPATHIES? In: Muscle & Nerve. WILEY-BLACKWELL; 2012. p. 664–5.
       Link to Item
    • Kushlaf HA, Juel VC, Hobson-Webb LD. SONOGRAPHICALLY-MEASURED NERVE SIZE AND INTRA-NERVE SIZE VARIABILITY IN INFLAMMATORY POLYNEUEROPATHY. In: Muscle & Nerve. WILEY-BLACKWELL; 2012. p. 664–664.
       Link to Item
    • Mhoon JT, Juel VC, Hobson-Webb LD. MEDIAN NERVE ULTRASOUND AS A SCREENING TOOL IN CARPAL TUNNEL SYNDROME: CORRELATION OF CROSS-SECTIONAL AREA MEASURES WITH ELECTRODIAGNOSTIC ABNORMALITY. In: Muscle & Nerve. WILEY-BLACKWELL; 2012. p. 675–6.
       Link to Item
    • Sanders DB, Burns TM, Cutter GC, Massey JM, Juel VC, Hobson-Webb L. DOES CHANGE IN ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) LEVEL PREDICT OR CORRELATE WITH CLINICAL CHANGE IN MG? In: Muscle & Nerve. WILEY-BLACKWELL; 2012. p. 678–678.
       Link to Item
    • Sanders DB, Massey JM, Juel VC, Hobson-Webb L. DOES THE PRESENCE OR LEVEL OF ACETYLCHOLINE RECEPTOR ANTIBODY (ACHR-AB) PREDICT GENERALIZATION IN OCULAR MYASTHENIA (OM)? In: Muscle & Nerve. WILEY-BLACKWELL; 2012. p. 678–678.
       Link to Item
    • Sanders DB, Massey JM, Juel VC, Hobson-Webb L. DOES THE ACETYLCHOLINE RECEPTOR ANTIBODY LEVEL PREDICT OR CORRELATE WITH THE OUTCOME IN MG? In: Muscle & Nerve. WILEY-BLACKWELL; 2012. p. 678–678.
       Link to Item
    • Hobson-Webb L, Juel V, Guptill J, Massey J, Sanders D. Can Mycophenolate Mofetil Be Successfully Tapered in Myasthenia Gravis? In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2012.
       Link to Item
    • Hobson-Webb L, Juel V, Guptill J, Massey J, Sanders D. Do Clinical Characteristics Predict Response to Mycophenolate Mofetil in Myasthenia Gravis? In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2012.
       Link to Item
    • DeCroos EC, Hobson-Webb L, Juel VC, Massey JM, Sanders DB. INCREASED OCCURRENCE OF LATE ONSET MYASTHENIA GRAVIS. In: Muscle & Nerve. WILEY-BLACKWELL; 2011. p. 690–690.
       Link to Item
    • DeCroos EC, Hobson-Webb L, Juel VC, Massey JM, Sanders DB. DO ANTIBODIES PREDICT THE PRESENCE OR ABSENCE OF THYMOMA IN MYASTHENIA GRAVIS? In: Muscle & Nerve. WILEY-BLACKWELL; 2011. p. 691–691.
       Link to Item
    • Guptill JT, Oakley D, Kuchibhatla M, Guidon A, Hobson-Webb LD, Massey JM, et al. PLASMA EXCHANGE COMPLICATIONS ARE RELATED TO THE VENOUS ACCESS ROUTE. In: Muscle & Nerve. WILEY-BLACKWELL; 2011. p. 691–2.
       Link to Item
    • Hobson-Webb LD, Mhoon JT, Juel VC. THE EFFECT OF TRANSUDCER FREQUENCY ON ULTRASONOGRAPHIC MUSCLE LUMINOSITY MEASURES. In: Muscle & Nerve. WILEY-BLACKWELL; 2011. p. 622–622.
       Link to Item
    • Mhoon JT, DeCroos EC, Massey JM, Juel VC, Hobson-Webb L. MEDIAN NERVE ULTRASOUND AS A SCREENING TOOL IN CARPAL TUNNEL SYNDROME. In: Muscle & Nerve. WILEY-BLACKWELL; 2011. p. 685–685.
       Link to Item
    • Howard JF, Barohn R, Cutter G, Freimer M, Juel V, Mozaffar T, et al. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER, PHASE II STUDY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG). In: Muscle & Nerve. WILEY-BLACKWELL; 2011. p. 689–90.
       Link to Item
    • Evoli A, Guptill JT, Batocchi A, Padua L, Massey JM, Juel VC, et al. Prognostic Value of Clinical Response to Acetylcholinesterase Inhibitors in Myasthenia Gravis with Anti-MuSK Antibodies. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2011. p. A286–7.
       Link to Item
    • Mhoon J, Choi E, Juel V, Hobson-Webb L. Correlation of Carpal Tunnel Severity to Ultrasonographic Median Nerve Cross Sectional Area. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2011. p. A521–2.
       Link to Item
    • Mhoon JT, Juel VC, Hobson-Webb LD, Massey JM. Ultrasound and Electrodiagnostic Findings in Acute Inflammatory Demyelinating Polyradiculoneuropathy with Facial Neuropathy. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2011. p. A523–A523.
       Link to Item
    • Juel VC, Hobson-Webb LD, Smith EC, Stickler DE, Selcen D, Engel AG. Fatal Muscular Dystrophy, Congenital Myasthenic Syndrome (CMS), and Epidermolysis Bullosa Simplex (EBS) Due to Plectin Deficiency. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2010. p. A109–10.
       Link to Item
    • Sanders D, Massey J, Juel V. MuSK antibody positive myasthenia gravis: Response to treatment in 31 patients. In: Neurology. 2007. p. A299–A299.
       Link to Item
    • Juel VC, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: Findings in 97 patients. In: Muscle & Nerve. JOHN WILEY & SONS INC; 2006. p. 543–543.
       Link to Item
    • Sanders DB, Juel VC, Massey JM. Muscle-specific kinase antibody myasthenia gravis: Response to treatment in 25 patients. In: Muscle & Nerve. JOHN WILEY & SONS INC; 2006. p. 542–3.
       Link to Item
    • Levy N, Aubourg P, Banwell B, Navarro C, Kalimo H, Figarella-Branger D, et al. X-linked myopathy with excessive autophagy: Genes exclusion in the Xq28 region and X-inactivation studies in obligate carriers. In: Journal of the Neurological Sciences. ELSEVIER SCIENCE BV; 2002. p. S105–S105.
       Link to Item
    • Juel VC, Johnston KC. Relationships between Resident Inservice Training Examination and neurology board examination performance. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2002. p. A21–2.
       Link to Item
    • Juel VC, Doyle LL, Miller JQ. Medical student performance of neurologic versus non-neurologic physical examinations on standardized patient examinations. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 2001. p. A31–A31.
       Link to Item
    • Alic SA, Aiyar R, Juel V, Mandell J, Villanova M, Fardeau M, et al. X-linked myopathy with excessive autophagy (XMEA): clinical spectrum, refined mapping and mutation screening. In: American Journal of Human Genetics. 2001. p. 538–538.
       Link to Item
    • Juel VC, Doyle LL, Miller JQ. Medical student performance on a simulated neurologic patient evaluation before neurology clerkship. In: Neurology. LIPPINCOTT WILLIAMS & WILKINS; 1999. p. A67–A67.
       Link to Item
    • Vern BA, LaGuardia J, Leheta BJ, Schuette WH, Juel VC. Correlation of increases in cortical blood volume and cytochrome aa(3) oxidation with enhanced gamma-electrocorticographic activity and eye movement bursts during REM sleep in cats. In: Annals of Neurology. LIPPINCOTT-RAVEN PUBL; 1997. p. T258–T258.
       Link to Item
    • VERN BA, GRAUPE P, LEHETA B, JUEL VC, SCHUETTE WH. INTERHEMISPHERIC SYNCHRONY OF LOW-FREQUENCY METABOLIC OSCILLATIONS IN UNANESTHETIZED CORTEX. In: Annals of Neurology. LITTLE BROWN CO; 1991. p. 267–267.
       Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • NEURO 403C: Clinical Neurology Subspecialties 2023
  • NEURO 206C: Primary Care Leadership Track (PCLT)-Neurology 2022
  • NEURO 403C: Clinical Neurology Subspecialties 2022
  • NEURO 205C: Neurology 2021
  • NEURO 206C: Primary Care Leadership Track (PCLT)-Neurology 2021
  • NEURO 209C: Longitudinal Integrated Curriculum - Neurology 2021
  • NEURO 402C: Neurology Clerkship 2021
  • NEURO 403C: Clinical Neurology Subspecialties 2021
  • NEURO 404C: Consultative Neurology 2021

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.